17q12-21 – The pursuit of targeted therapy in breast cancer

This publication has 51 references indexed in Scilit:

• Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARβ/δ to RAR
  Proceedings of the National Academy of Sciences, 2008
• Expression of HER2 and the Coamplified Genes GRB7 and MLN64 in Human Breast Cancer: Quantitative Real-time Reverse Transcription-PCR as a Diagnostic Alternative to Immunohistochemistry and Fluorescence In situ Hybridization
  Clinical Cancer Research, 2005
• Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
  New England Journal of Medicine, 2005
• A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
  New England Journal of Medicine, 2004
• Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis
  Oncogene, 2004
• The discovery of receptor tyrosine kinases: targets for cancer therapy
  Nature Reviews Cancer, 2004
• Repeated observation of breast tumor subtypes in independent gene expression data sets
  Proceedings of the National Academy of Sciences, 2003
• ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
  The EMBO Journal, 1997
• Co-amplification of erbB2, topoisomerase II α and retinoic acid receptor α genes in breast cancer and allelic loss at topoisomerase I on chromosome 20
  European Journal Of Cancer, 1993
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987